tbuckley/cabot-search huggingface dataset:
1865P DEFENDOR special: Real-world use of pegylated granulocyte-colony stimulating factor in patients with gastrointestinal cancers
Authors: A. Tryakin, E. Dinaeva, M. Fedyanin, A. Margusheva, I. Avdyukhin, O. Prosianikova, I. Sorokina
Journal: Annals of Oncology (2024)
1963O JCOG1019: An open-label, non-inferiority, randomised phase III study comparing the effectiveness of watchful waiting (WW) and intravesical Bacillus Calmette-Guérin (BCG) in patients (Pts) with high-grade pT1 (HGT1) bladder cancer with pT0 on the second transurethral resection (TUR) specimen
Authors: H. Kitamura, J. Mizusawa, T. Shibata, K. Sasaki, K. Hashine, K. Fujimoto, K. Hashimoto, T. Kobayashi, S. Narita, T. Kimura, M. Sugimoto, Y. Matsui, S. Hatakeyama, M. Eto, H. Nishiyama
Journal: Annals of Oncology (2024)
1893P Incidence of myocardial ischemia during treatment with capecitabine: Assessment with Holter recording and cardiac biomarkers
Authors: A. Dyhl-Polk, M. Schou, K. Kjeldgaard Vistisen, A-S. Sillesen, S.E. Bojesen, J. Faber, M. Vaage-Nilsen, D.L. Nielsen
Journal: Annals of Oncology (2024)
1858P Efficacy and safety of thromboprophylaxis in oncology patients with Khorana score&lt;2: Combined results from GMaT and ACT4CAT studies
Authors: N.G. Tsoukalas, A.N. Christopoulou, E. Timotheadou, A. Koumarianou, A. Ardavanis, I. Athanasiadis, M. Demiri, A. Bokas, G.F. Samelis, S. Peroukidis, G. Papatsimpas, C. Andreadis, C. Kalofonos, A. Psyrri, N. Kapodistrias, P. Papakostas, E. Samantas, G. Aravantinos, P. Papakotoulas, I. Boukovinas
Journal: Annals of Oncology (2024)
1853P Risk model for overall survival (OS) based on composite patient-reported outcomes (PROs) in aNSCLC patients treated with first-line (1L) cemiplimab-based therapy
Authors: D.R. Gandara, M. Gogishvili, A. Sezer, T. Makharadze, M. Gumus, E. Yan, J. Harnett, P. Rietschel, R. Quek
Journal: Annals of Oncology (2024)
LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC)
Authors: B.J. Monk, A. Oaknin, D.M. O'Malley, M. Wilson, D. Lorusso, S. Westin, A.M. Oza, F. Zagouri, T.J. Herzog, O. Mikheeva, C. Parkinson, R.L. Coleman, M.C. Lim, A.M. Chudecka-Glaz, R.N. Eskander, I. Bruchim, S. Ghamande, D. Despain, K. Fujiwara, R. Kristeleit
Journal: Annals of Oncology (2024)
LBA82 Efficacy and safety of ponsegromab, a first-in-class, monoclonal antibody inhibitor of growth differentiation factor 15, in patients with cancer cachexia: A randomized, placebo-controlled, phase II study
Authors: J. Crawford, J.D. Groarke, S.M. Collins, S. Lubaczewski, E.J. Roeland, T. Naito, A.E. Hendifar, M.T. Fallon, K. Takayama, T.R. Asmis, R.F. Dunne, M. Rossulek, R. Qiu, A.R. Saxena
Journal: Annals of Oncology (2024)
1856P Prediction of clinically significant bleeding in anticoagulated patients for cancer-associated venous thromboembolism: Validation of B-CAT score in a cohort from the TESEO study
Authors: J. López Robles, M. Sanchez Canovas, C. Iglesias Pérez, L. Ortega Morán, L. Sánchez Togneri, J. Rubio Perez, I. Fernandez Perez, M. Garcia De Herreros, I. Garcia Escobar, R. Porta-Balanya, E.M. Brozos Vazquez, M. Carmona Campos, E. Martinez de Castro, H. Olivares Barreiro, T. Quintanar Verduguez, S. Garcia-Adrian, M. Covela, M.E. Guirao García, P. Jimenez Fonseca, A.J. Munoz Martin
Journal: Annals of Oncology (2024)
1965MO Phase II study of futibatinib plus pembrolizumab in patients (pts) with advanced/metastatic urothelial carcinoma (mUC): Final analysis of efficacy and safety
Authors: V.S. Koshkin, P. Barthelemy, G. Gravis, O. Goodman, I. Duran, R. Girones Sarrio, C. Hwang, J. Garcia-Donas, R. Morales Barrera, S. Zanetta, M. Chisamore, M. Liu, M. Gil, G. Tomlinson, H. Elsayed, Y. Loriot
Journal: Annals of Oncology (2024)
LBA65 Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH)
Authors: O. Sartor, D.M. Jiang, M. Smoragiewicz, M. Zibelman, A. Flechon, G. El-Haddad, G. Abikhzer, F. Saad, R. Tutrone, S.T. Tagawa, U. Metser, J. Calais, A.R. Hansen, W. Wu, J. Jensen, C.R. Trieu, N. Fleshner, I. Teslenko, J-C.G. Provost, K.N. Chi
Journal: Annals of Oncology (2024)
220P The role of fucosyltransferase 1 (FUT1) in CRC as a putative prognostic and predictive biomarker
Authors: L.M. Pammer, M. Guenther, R. Gruber, S. Ormanns, A. Martowicz, A. Amann, F.I. Nocera, M. Abdel Hamid, F. Kocher, E. Gasser, S. Gasteiger, K. Esswein, G. Widmann, A. Joebstl, Z. Trajanoski, A. Puccini, A. Seeber
Journal: Annals of Oncology (2024)
1961O Nivolumab plus chemoradiotherapy in patients with non-metastatic muscle-invasive bladder cancer (nmMIBC), not undergoing cystectomy: A phase II, randomized study by the Hellenic GU Cancer Group
Authors: A. Kougioumtzopoulou, K. Koutsoukos, R. Zakopoulou, K. Tzannis, A. Kyriazoglou, A. Damatopoulou, M. Liontos, M.K. Pispirigkou, K. Ntoumas, K. Stravodimos, D. Mitropoulos, A. Dellis, A. Papatsoris, M. Chrisofos, D. Kardamakis, A. Zygogianni, Z. Liakouli, G. Pissakas, A. Bamias, V. Kouloulias
Journal: Annals of Oncology (2024)
LBA46 Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab
Authors: C. Robert, M.M. Milhem, J.J. Sacco, J. Michels, G.K. In, E. Muñoz-Couselo, D. Schadendorf, G.M. Beasley, J.J. Niu, B. Chmielowski, T.M. Wise-Draper, T.L. Bowles, K.K. Tsai, C. Lebbe, C. Gaudy Marqueste, M.R. Middleton, A. Samson, J. Zhu, M. Viana, M.K.K. Wong
Journal: Annals of Oncology (2024)
1983P Feasibility and efficacy of split-dose cisplatin with atezolizumab for cisplatin-ineligible urothelial carcinoma (SOGUG-AUREA): Final results
Authors: G.A. De Velasco Oria, I. García-Carbonero, E. Esteban-Gonzalez, A. Pinto, D. Lorente, A. Gomez de Liano Lista, E. Martínez Ortega, L. Jimenez Colomo, J. Puente, I. Gonzalez, O. Fernandez Calvo, G. Anguera
Journal: Annals of Oncology (2024)
1857P Machine learning models (MLM) predict venous thromboembolism events (VTE) in Asian oncological inpatients better than the Khorana Score (KS)
Authors: J. Loh, X.J. Guo, M.S. Furqan, E.S. Yap, S.C. Lee, K.Y. Ngiam, C.E. Chee, K.B. Nesaretnam
Journal: Annals of Oncology (2024)
1863P Circulating biomarkers for risk stratification of cancer patients with chemotherapy associated febrile neutropenia
Authors: S. Wikström Fernandez, P. Torrella Esteban, A. Murillo Herrera, P. Garrido Ortega, E. Feliciangeli, P. Cerezuela-Fuentes, L. García de Guadiana–Romualdo
Journal: Annals of Oncology (2024)
LBA29 Final overall survival (OS) in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) treated with niraparib (nir) first-line (1L) maintenance: Results from PRIMA/ENGOT-OV26/GOG-3012
Authors: A. González-Martín, B. Pothuri, M.P. Barretina Ginesta, W.S. Graybill, I.B. Vergote, C. McCormick, M.R. Mirza, R.G. Moore, D. Lorusso, R.E. O'Cearbhaill, G. Freyer, D.M. O'Malley, F. Heitz, M.S. Shahin, I. Bruchim, W.H. Bradley, N. Compton, I. Malinowska, A. Redondo, B.J. Monk
Journal: Annals of Oncology (2024)
Basal/squamous and Mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial
Authors: C.S. Groeneveld, C. Pfister, S. Culine, V. Harter, C. Krucker, J. Fontugne, V. Dixon, N. Sirab, I. Bernard-Pierrot, A. de Reyniès, F. Radvanyi, Y. Allory, G. Pignot, J.P. Fendler, L. Guy, G. Verhoest, N. Mottet, A. Doerfler, S. Abadie-Lacourtoisie, A. Azzouzi, P. Mongiat, L. Geoffrois, P. Eschwege, F. Di Fiore, G. Roubaud, J.L. Hoepffner, P. Barthelemy, H. Lang, E. Voog, E. Mandron, J.M. Tourani, C. Serrrate, A. Colau, C. Saldana, A. de La Taille, T. Nguyen, F. Kleinclauss, Y. Loriot, J. Irani, J.C. Eymard, S. Larre, O. Huillard, M. Zerbib, F. Rolland, J. Rigaud, N. Houede, S. Droupy, G. Malouf, M. Roupret, S. Vieillot, N. Letang, T. Lharidon, N. Gaschignard, W. Hilgers, J.L. Davin
Journal: Annals of Oncology (2024)
1989P Efficacy of enfortumab vedotin (EV) in patients (pts) with (w) advanced urothelial carcinoma (aUC) who have baseline neuropathy (N) and/or diabetes mellitus (DM): A UNITE study analysis
Authors: A. Jang, T. Jindal, C.Y. Jiang, C.B. Nguyen, A. Nizam, A.S. Alva, P. Grivas, J. Bellmunt, C.J. Hoimes, M.A. Bilen, H. Emamekhoo, M.I. Milowsky, A.R. Khaki, S. Gupta, M.T. Campbell, O. Alhalabi, Z. Chen, P. Fu, V.S. Koshkin, J.R. Brown
Journal: Annals of Oncology (2024)
1869P Risk factors for reduced relative dose intensity (RDI) in patients with solid tumors receiving chemotherapy (CT) and primary prolonged G-CSF prophylaxis by empegfilgrastim: Analysis of DEFENDOR study
Authors: A. Snegovoy, I.B. Kononenko, I. Sorokina, P. Kiseleva, O. Mironenko, A. Berezina, O. Prosianikova
Journal: Annals of Oncology (2024)
LBA84 TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): Interim analysis of SunRISe-4 (SR-4)
Authors: A. Necchi, F. Guerrero-Ramos, P.L. Crispen, B. Herrera Imbroda, R. Garje, T.B. Powles, C.C. Peyton, B. Pradere, J.H. Ku, N.D. Shore, M. Boegemann, M.A. Preston, E. Xylinas, C. Gong, S. Najmi, M. Hasan, H. Stitou, S. Bhanvadia, H. Sweiti, S.P. Psutka
Journal: Annals of Oncology (2024)
1959O BL-B01D1, an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic urothelial carcinoma (UC)
Authors: D. Ye, X. Bian, T. Yang, S. Jiang, M. Cao, X. Hua, S. Xiao, H. Wang, H. Zhu, Y. Zhu
Journal: Annals of Oncology (2024)
1915P Phase I trial of adjuvant pembrolizumab after radiation therapy for lung-intact malignant pleural mesothelioma
Authors: M.S. Ning, S. Gandhi, D.R. Gomez, J.Y. Chang, G. Blumenschein, D. Rice, M. O'Reilly, B. Sepesi, S.H.H. Lin, Z. Liao, X. Le, L.A. Byers, R. Mehran, W. Hofstetter, M. Hernandez, Y-S. Chen, M. Jeter, A.S. Tsao
Journal: Annals of Oncology (2024)
1970MO Circulating tumor DNA (ctDNA) clearance with neoadjuvant durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) from the safety run-in cohort of the phase III VOLGA trial
Authors: A. Drakaki, T.B. Powles, Y. Wang, M. Bupathi, M. Joshi, M.T. Fleming, A. Gomez de Liano Lista, R. Morales Barrera, R. Pili, S. Boulos, Y. Shrestha
Journal: Annals of Oncology (2024)
1926MO Radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients treated with lenvatinib monotherapy: Real-world treatment patterns and clinical outcomes in Europe and Canada
Authors: L.D. Locati, T. Alonso Gordoa, L. Lamartina, M. Luster, O. Rajkovic-Hooley, N. Reynolds, G. Milligan, C. Cooper, I. Brown, H. Saal, J.R. Borbolla Escoboza, K. Newbold
Journal: Annals of Oncology (2024)
1932P Tyrosine kinase inhibitors-induced erythrocytosis in thyroid cancers: A novel safety signal from a retrospective study
Authors: S. Marchesi, A. Spagnoletti, F. Barretta, S. Buriolla, M. De Monte, C. Sciortino, S. Demurtas, L. Meschia, I. Nuzzolese, C. Bergamini, S. Cavalieri, E. Colombo, A. Ottini, M. Salvetti, B. Paolini, A. Guidetti, M. Carpenedo, L.F.L. Licitra, L.D. Locati, S. Alfieri
Journal: Annals of Oncology (2024)
LBA37 Final results: Randomized assessment of cisplatin dosing interval for ototoxicity (RADIO) trial comparing chemoradiation (CRT) with cisplatin q3weekly to weekly for locally advanced squamous cell carcinoma of the head and neck (LASCCHN)
Authors: M.S. Kuruvilla, B. Meyers, M. Smoragiewicz, P. Stewart, S. Ghedira, L. Bordeleau, K.K. Chan, S.J. Hotte, C. Parker, D. Palma, D-H. Kim, I. Karam, P. Lang, N. Read, V. Venkatesan, A. Nichols, A.V. Louie, R. Kim, G. Pond, E. Winquist
Journal: Annals of Oncology (2024)
LBA41 Long-term survival with neoadjuvant therapy in melanoma: Updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
Authors: G.V. Long, C.U. Blank, R.N. Amaria, T.J. Hieken, S.K. Sandhu, M.J. Barros, T.C.C. Mitchell, Z. Eroglu, I.V. Samoylenko, P. Rutkowski, D. Johnson, I. Pires da Silva, K.A. Perry, H.A. Tawbi, M.S. Block, P.A. Ascierto, E. Burton, A.C.J. van Akkooi, R.A. Scolyer, A.M. Menzies
Journal: Annals of Oncology (2024)
1925MO Regomune study: A phase II study of regorafenib + avelumab in solid tumors. Results of the radioiodine-refractory differentiated thyroid cancer (RR-DTC)
Authors: Y. Godbert, S. Cousin, C. Bellera, J-P. Guégan, J. Hadoux, C.A. Gomez-Roca, P. Cassier, S. Hescot, M. Vinches, C. Cantarel, J. Palussière, M. Kind, I. Soubeyran, A. Bessede, A. Italiano
Journal: Annals of Oncology (2024)
191P Understanding and overcoming resistance to selective FGFR inhibitors across FGFR2-driven tumors
Authors: F. Facchinetti, Y. Loriot, F. Brayé, D. Vasseur, R. Bahleda, L. Bigot, R. Barbe, C. Nobre, D. Combarel, S. Michiels, A. Italiano, C. Smolenschi, L. Tselikas, J. Scoazec, S. Ponce Aix, B. Besse, F. André, K.A. Olaussen, A. Hollebecque, L. Friboulet
Journal: Annals of Oncology (2024)
1948P Analysis of cytokines, chemokines, and tumor-infiltrating lymphocytes as immunological markers predicting pathological complete response in triple-negative breast cancer: Exploratory analysis of the NACATRINE trial
Authors: A.J.A. de Freitas, W.Y. Hirai, C.R. Nunes, R.L. Causin, I.V.V. Santana, S. Calfa, C. de Pádua Souza, M.M.C. Marques
Journal: Annals of Oncology (2024)
228TiP FINPROVE: The Finnish national study to facilitate patient access to targeted anti-cancer drugs
Authors: M.V.J. Mustonen, E. Alanne, S.M.E. Iivanainen, O-S. Kääriäinen, M.M.E. Tanner, J. Mattson, K. Jalkanen
Journal: Annals of Oncology (2024)
1988P Enfortumab vedotin (EV) + pembrolizumab (P) outcomes outside clinical trials and biomarkers of benefit in patients (pts) with advanced urothelial carcinoma: Analysis of the UNITE study
Authors: T. Jindal, C.Y. Jiang, O. Alhalabi, I. Tsung, A. Jang, D.R. Bakaloudi, F. Sidhom, A.K. Taylor, C.J. Hoimes, J. Bellmunt, M.A. Bilen, S. Gupta, M.I. Milowsky, S. Shah, A. Basu, P. Grivas, J.R. Brown, M.T. Campbell, A.S. Alva, V.S. Koshkin
Journal: Annals of Oncology (2024)
LBA70 Adding metformin to androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC): Overall survival (OS) results from the multi-arm, multi-stage randomised platform trial STAMPEDE
Authors: S. Gillessen, L.R. Murphy, N.D. James, A. Sachdeva, G. Attard, R.J. Jones, A. Adler, O. El-Taji, M. Varughese, J. Gale, S.J. Brown, N.N. Srihari, R. Millman, D. Matheson, C.L. Amos, C. Murphy, C. McAlpine, M.K. Parmar, L.C. Brown, N. Clarke
Journal: Annals of Oncology (2024)
1880P Antiemetic prophylaxis during chemoradiation: Sub-study of the GAND-emesis trial identifying dosimetric predictors for vomiting
Authors: A.M. Johannsdottir, C. Brink, A. Knudsen, J. Lindegaard, N. Jensen, T.Z. Iversen, L.H. Dohn, I. Hazell, G-B. Nyvang, J. Herrstedt, C.H. Ruhlmann
Journal: Annals of Oncology (2024)
1922P Targeted resequencing designed specifically for thymic epithelial tumours confirmed the high prevalence of GTF2I mutations
Authors: I. Petrini, E. Pardini, F. Cucchiara, G. Sardo Infirri, I.S. Burzi, S. Barachini, M. Monatli, M. Maestri, R. Ricciardi, V. Nicolì, F. Coppedè, D. Bacchin, F. Melfi, V. Aprile, M. Lucchi
Journal: Annals of Oncology (2024)
1910MO ARTIMES: Automated response evaluation to treatment in mesothelioma
Authors: K.B.W. Groot Lipman, R. Wittenberg, M. de Oliveira Taveira, I. Smesseim, A. Schmitz, T. Boellaard, K. Chupetlovska, M. Abdelatty Elsayed, L. Petrychenko, N. Jain, F. Arico, A. Bajaj, D.A. Fennell, A. Curioni-Fontecedro, T.D.L. Nguyen-kim, R. Tissier, P. Baas, S. Burgers, D. De Gooijer, S. Trebeschi
Journal: Annals of Oncology (2024)
1896P Importance of prompt medical oncologist (MO) consultation at the Emergency Department (ED): A prospective study in a tertiary hospital on 10,896 admissions in the first quarter of 2024
Authors: C. Morelli, M. Mea, M.V. Bonomo, A. Meacci, T. Naccarelli, M. Rofei, G. Parisi, V. Flaminio, S. Riondino, V.N. Di Lecce, C. Paganelli, J.M. Legramante, M. Roselli, V. Formica
Journal: Annals of Oncology (2024)
1982P Post hoc analysis of outcomes according to prior chemotherapy (CT) response and platinum agent in the international SAUL study of atezolizumab (atezo) for urinary tract carcinoma (UTC)
Authors: B. Perez Valderrama, X. Garcia Del Muro, A.S. Merseburger, Y. Loriot, E. Choy, D.E. Castellano Gauna, F. Lopez-Rios, T. Bonfill Abella, A. Montesa Pino, P. Yu, P. Skamnioti, C.N. Sternberg
Journal: Annals of Oncology (2024)
1895P Higher modified Glasgow Prognostic Score in cancer patients at the Emergency Department is associated with an increased risk of hospital admissions
Authors: D.F-X. Huber, S. Pasalic, A.M. Starzer, J.M. Berger, C. Englisch, M. Kleinberger, G. Jeryczynski, M. Mair, T. Fuereder, R. Bartsch, A.S. Berghoff, M. Preusser, C. Minichsdorfer
Journal: Annals of Oncology (2024)
1991P Subgroup analyses of patients (pts) with advanced urothelial carcinoma (aUC) who had long-term progression-free survival (PFS) or overall survival (OS) with avelumab first-line maintenance (1LM) in the AVENANCE real-world study
Authors: P. Barthelemy, J-C. Eymard, A. Flechon, M. Gross Goupil, E. Voog, Y. Loriot, C. Abraham Jaillon, A. Gobert, M. Chasseray, E. Kazan, C. Josse, P. Lambert, L. Paret, C. Thibault
Journal: Annals of Oncology (2024)
1890P End-of-Life (EOL) systemic anticancer treatment (SACT) and health services use before and during the COVID-19 pandemic
Authors: J. Iqbal, R. Moineddin, R.A. Fowler, C.M. Booth, J. Downar, J. Lau, L. Le, G.M. Rodin, H. Seow, P. Tanseputro, C. Earle, K.L. Quinn, M.K. Krzyzanowska, B. Hannon, C. Zimmermann
Journal: Annals of Oncology (2024)
1945P Stroma-derived bIgH3 (βigH3/TGFBI) is the local mediator of pathological TGFβ activity in pancreatic cancer and a target to treat in patients with high fibrotic activity
Authors: M.A. Karsdal, N. Willumsen, C. Bager, N.I. Nissen, A. Teo Hansen Selnø, K.E. Mohamed, R.S. Pedersen, I. Chen, J.S. Johansen, K. Henriksen
Journal: Annals of Oncology (2024)
1850P Management and potential factors of immunotoxicity in patients with metastatic non-small cell lung cancer receiving first-line treatment with immune checkpoint inhibitors
Authors: J. Peña-Lopez, D. Jiménez Bou, L. Gutierrez Sainz, I. Ruiz-Gutiérrez, J.I. Alonso-Eiras, C. Navas-Jiménez, Á. García-Zamarriego, M. Bescos-Royo, M.L. González-García, L. Martín-Morales, A. Rueda Lara, M. Alameda, G. Martin-Montalvo Perez, J. Villamayor Sanchez, P. Cruz Castellanos, O. Higuera Gomez, J. de Castro Carpeño
Journal: Annals of Oncology (2024)
1852P The use of patient-reported outcome measures to assess toxicities and quality of life associated with immune checkpoint inhibitor therapy: A systematic review
Authors: P.P. Jaganathan, S. Georgopoulou, J.M. Droney, P. Howell, A. Macklin-Doherty, K. Young, S. Cruickshank
Journal: Annals of Oncology (2024)
1883P Impact of geriatrician-implemented Interventions on chemotherapy (CT) delivery in vulnerable elderly patients with early or advanced solid tumors: The GIVE trial
Authors: E. Risi, A. Brunello, C. Biagioni, D. Calvani, S. Di Donato, E. Moretti, F. Bergamo, D. Pozzessere, E. Zafarana, G.G. Baldi, E. Mori, V.E. Palmieri, A. Luciani, L. Fratino, F. Del Monte, L. Malorni, D. Becheri, N.M.L. Battisti, G. Mottino, L. Biganzoli
Journal: Annals of Oncology (2024)
1931P Phase II study of PDR001 in combination with MAPK pathway inhibitors in patients with radioactive-refractory differentiated thyroid cancer (DTC)
Authors: W. Wong, E.J. Sherman, A. Kriplani, L. Michel, I. Zhi, T.K.W. Hung, L. Dunn, R.K. Grewal, G. Krishnamoorthy, I. Ostrovnaya, N. Katabi, J. Fagin, D. Pfister, A.L. Ho
Journal: Annals of Oncology (2024)
1947P Organoid establishment from multiple biological sources in biliopancreatic cancers
Authors: M. Zanoni, M. Cortesi, C. Binda, P. Giuffrida, C. Coluccio, S. Fabbri, T. Rossi, S. Bandini, M. Valgiusti, G. La Barba, A. Passardi, F. Limarzi, A. Cucchetti, C. Gallio, L. Esposito, G.L. Frassineti, G. Ercolani, I.G. Rapposelli, C. Fabbri, P. Ulivi
Journal: Annals of Oncology (2024)
1992P Real-world (RW) characteristics and outcomes in patients (pts) with muscle-invasive urothelial carcinoma (MIUC) treated with adjuvant nivolumab (NIVO) with or without neoadjuvant chemotherapy (NAC)
Authors: H. Ebrahimi, R. Barragan-Carrillo, W.S. John, S. Lucht, T. Miller, P. Pathak, E. Bland, S. Gordon, J. Laney, A.J. Klink, B.A. Feinberg, N. Singh, C. Alonso, M. Patel, L.C. Rosenblatt, X. Yin, A. Chehrazi-Raffle
Journal: Annals of Oncology (2024)
1951P A multicenter, retrospective study of non-small-cell lung carcinoma (NSCLC) harboring EGFR exon 20 insertions: Distribution, variants, and prevalence of coalterations
Authors: I.G. Sullivan, M. Garzón, U. Malapelle, R. de Oliveira Cavagna, A. Aguilar Hernandez, A.A. Valdivia, R.M. Reyes Cabanillas, S. Clave, M. Saigi Morgui, È. Sais, M.A. Mosteiro Lamas, S. Calabuig Fariñas, A. Barba Joaquín, M. Fernandez Bruno, J.N. Minatta, S. Viteri, M.V. Bluthgen, J. Pandolfi, C. Mayo de las Casas, R. Rosell
Journal: Annals of Oncology (2024)
1977P Efficacy of talazoparib and avelumab as a maintenance treatment in patients with advanced/metastatic urothelial carcinoma (mUC) whose disease did not progress after a first-line platinum-based chemotherapy (PBCT): The GETUG-TALASUR trial
Authors: E. Coquan, E. Boughalem, D. Pouessel, J. Lequesne, F. Calcagno, J-M. Grellard, F. Christy, H. Mahammedi, S. Ladoire, D. Borchiellini, R. Leman, C. Bazille, J. Fontugne, L. Crouzet, A. Flechon, C. Serrate, G. Gravis, B. Clarisse, A. Thiery Vuillemin, F. Joly Lobbedez
Journal: Annals of Oncology (2024)
1975P Avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC): Conditional survival and long-term safety in patients (pts) treated for ≥1 or ≥2 years in JAVELIN Bladder 100
Authors: P. Grivas, S.H. Park, E. Voog, W-P. Su, W. Demey, P.C. Fong, J.A. Garcia, N. Jacob, A. Gerhold-Ay, K. Tyroller, J. Hoffman, J. Bellmunt, T.B. Powles
Journal: Annals of Oncology (2024)
1879P Effectiveness of intravenous fosnetupitant &amp; palonosetron for cinv prophylaxis in patients receiving highly emetogenic chemotherapy regimens: Subgroup analysis from a phase IV Indian study
Authors: A.K. Verma, A. Pednekar, H.B. Barkate, P. Shukla, S. Valame, S. Nanda, N.K. Shakya, A. Hanji, S. Patil, S.B. Bhagat, S. Bhushan
Journal: Annals of Oncology (2024)
1854P Assessing mortality rates within 30 days following the last dose of immunotherapy: A multi-center retrospective study
Authors: K. Baskurt, O. Akdogan, Y. Sagdic Karateke, I. Deliktas Onur, O. Yazici, B. Yildiz, C. Karacin, B.O. Oksuzoglu, O. Sutcuoglu
Journal: Annals of Oncology (2024)
1985P Retrospective database analysis of real-world treatment patterns and sequencing in locally advanced or metastatic urothelial carcinoma patients receiving sacituzumab govitecan
Authors: R. Mamtani, J. Katz, R. An, F. Boateng, Y. Ghazi, M. Brockman, M. Sierecki
Journal: Annals of Oncology (2024)
1933P Utility of circulating tumoral DNA analysis by multi-gene NGS panels in tracking therapy progression of advanced sporadic medullary thyroid carcinoma
Authors: R. Ciampi, T. Ramone, A. Matrone, A. Prete, C. Gambale, R. Casalini, C. Romei, F. Panebianco, R. Elisei
Journal: Annals of Oncology (2024)
1861P Poly (ADP-Ribose) polymerase inhibitors (PARPI): Associated thrombosis in patients with ovarian cancer
Authors: M. Sanchez Canovas, J. López Robles, F.J. Garcia Verdejo, D. Cacho Lavin, S. Guirao, A. Garrido Fernandez, E. Coma Salvans, T. Quintanar Verduguez, C. Salvador Coloma, D. Fernandez Garay, J.D. Cumplido, A.I. Ferrer Perez, A. Carbo Bague, F.J. Teigell Muñoz, A.J. Munoz Martin
Journal: Annals of Oncology (2024)
1968P Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) + pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC)
Authors: J.E. Rosenberg, D.P. Petrylak, T. Flaig, C.J. Hoimes, S. Gupta, P.H. O'Donnell, N. Mar, T. Friedlander, S.T. Tagawa, M.A. Bilen, J.R. Brown, R.R. McKay, J.R. Merchan, S. Srinivas, A. Shetty, B. Homet Moreno, G. Davis, H. Wirtz, Y. Zhu, M.I. Milowsky
Journal: Annals of Oncology (2024)